Table 4 Overview of the main ongoing or closed but still not reported clinical trials that involve taxanes

Trials not recruiting or completed

NO17629

AC × 4 → D₁₀₀ × 4 versus AC × 4 → D₇₅X × 4

1,810 node-positive and high-risk node-negative patients

NSABP B-38

ACD × 6 versus AC × 4 (q2w) → P × 4 (q2w) versus AC × 4 (q2w) → PG × 4 (q2w)

4,800 node-positive patients; DFS (primary); OS, recurrence and distant recurrence-free interval and toxicity (secondary)

CT/04.22

FEC × 4 (q2w) → D × 4 (q2w) versus FEC × 4 (q2w) → P × 4 (q2w)

478 node-positive patients; DFS (primary); OS, recurrence rate, toxicity and QoL (secondary)

GEICAM 2003-10

EC × 4 → D × 4 versus ED × 4 → X × 4

1,382 node-positive patients; DFS (primary); OS, toxicity, QoL, SNP predictors and molecular markers (secondary)

GEICAM 2003-02

FAC × 6 versus FAC × 4 → P × 8w

1,920 high risk node-negative patients; DFS (primary); OS, toxicity, QoL and prognostic gene profile (2)

Trials actively recruiting

CALGB-40101

AC × 4 (q2w) versus AC × 6 (q2w) versus P × 4 (q2w) versus P × 6 (q2w)

4,646 with 0 to 3 positive nodes patients; DFS (primary); OS, local control, time to distant metastasis, toxicity, amenorrhea, MDR1 haplotype effect, CYP polymorphism effect

LMU-ADEBAR

EF (d1, d8) C (oral d1–14) × 6 (q4w) versus EC (d1, d21, d42, d63) → D (d84, d105, d126,147)

446 node-positive patients; time to progression (primary); OS, toxicity and QoL (secondary)

SWOG-S0221

AC × 6 (q2w) → P × 6 (q2w) versus AC × 6 (q2w) → P × 12(w) versus AC × 15 (Aw, C oral d1–7) → P × 6 (q2w) versus AC × 15 (Aw, C oral d1–7) → P × 12(w)

4,500 node-positive and high-risk node-negative patients; DFS (primary); OS, toxicity and prognostic markers (secondary)

CT/01.04

D₇₅ × 4 → E₉₀ × 4 versus E₇₅D₇₅ × 6

724 high-risk node-negative patients; DF interval (primary); OS and safety (secondary)

USO 06090

TAC × 6 versus TC × 6

HER2 negative and node-positive and high-risk node-negative patients; DFS (primary)